Medidur™, pictured below the pencil, is an injectable micro-insert designed to treat posterior uveitis. Injected into the back of the eye, it provides sustained release of 0.18 mg of a corticosteroid directly to the retina at a controlled rate for three years. This technology used in Medidur, developed by pSivida Corp., can deliver small molecule drugs at consistent release rates for pre-determined period of time – weeks, months or years – and underlies three of only four FDA-approved sustained release treatments for back-of-the-eye diseases. pSivida announced highly statistically-significant results of the first of two Phase 3 trials for Medidur for posterior uveitis.
Medidur™, pictured below the pencil, is an injectable micro-insert designed to treat posterior uveitis. Injected into the back of the eye, it provides sustained release of 0.18 mg of a corticosteroid directly to the retina at a controlled rate for three years. This technology used in Medidur, developed by pSivida Corp., can deliver small molecule drugs at consistent release rates for pre-determined period of time – weeks, months or years – and underlies three of only four FDA-approved sustained release treatments for back-of-the-eye diseases. pSivida announced highly statistically-significant results of the first of two Phase 3 trials for Medidur for posterior uveitis.